Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GB 268

Next Previous
Drug Profile

GB 268

Alternative Names: GB-268

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genor Biopharma
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 26 Feb 2026 Phase-I clinical trials in Solis tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (unspecified route), prior to February 2026 (NCT06934616) (Genor Biopharma pipeline, February 2026)
  • 07 May 2025 Genor Biopharma plans a phase I trial for Solid tumours (Late stage disease) in April 2025 (IV; Infusion) (NCT06934616)
  • 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top